Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 10,076 shares at $19.43 ($196K) on 2023-10-04, disclosed to the SEC on 2023-10-06.
Scheduled sale ($196k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.43 | 4,594 | $89K | 45.5% |
| 2 | $19.43 | 4,594 | $89K | 45.5% |
| 3 | $19.91 | 888 | $18K | 9.0% |
| Total | $19.47 avg | 10,076 | $196K | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |